BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 276 filers reported holding BIO-TECHNE CORP in Q2 2017. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $4,595,000 | -3.4% | 31,060 | -1.4% | 0.08% | -8.0% |
| Q1 2018 | $4,759,000 | +15.2% | 31,505 | -1.2% | 0.09% | +17.3% |
| Q4 2017 | $4,130,000 | +9.7% | 31,875 | +2.3% | 0.08% | +4.2% |
| Q3 2017 | $3,765,000 | +3.9% | 31,148 | +1.1% | 0.07% | -2.7% |
| Q2 2017 | $3,622,000 | +22.6% | 30,820 | +6.0% | 0.07% | +12.1% |
| Q1 2017 | $2,955,000 | +30.1% | 29,064 | +31.6% | 0.07% | +20.0% |
| Q4 2016 | $2,272,000 | -4.3% | 22,090 | +1.9% | 0.06% | -11.3% |
| Q3 2016 | $2,373,000 | -3.2% | 21,675 | -0.3% | 0.06% | -7.5% |
| Q2 2016 | $2,452,000 | +17.9% | 21,740 | -1.2% | 0.07% | +8.1% |
| Q1 2016 | $2,079,000 | +10.5% | 21,996 | +5.2% | 0.06% | 0.0% |
| Q4 2015 | $1,881,000 | +18.6% | 20,899 | +21.8% | 0.06% | +6.9% |
| Q3 2015 | $1,586,000 | -9.8% | 17,154 | -4.0% | 0.06% | -9.4% |
| Q2 2015 | $1,759,000 | -2.0% | 17,863 | -0.1% | 0.06% | -5.9% |
| Q1 2015 | $1,794,000 | +9.3% | 17,888 | +0.6% | 0.07% | +1.5% |
| Q4 2014 | $1,642,000 | – | 17,776 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |